BUSINESS, POLICY AND TECHNOLOGY SESSIONS
Technologies and regulations are developing at an unprecedented pace; staying on the cutting-edge is crucial to your bottom line. The 2012 DMC and Technology Expo is your ticket to over 20 top-notch educational sessions — presented by industry thought leaders, government experts and academia — on the pressing topics affecting your business.
What Sessions Are Right For You?
Business discipline icons are listed by each educational session to help you determine which business, policy and technology sessions are right for you.
| Education Sessions Key | |||
 Click on the icons below to see what sessions apply to that particular business discipline. |
|||
 |
E-Business, MIS/IT, E-Commerce, Technical |  |
Track & Trace, Pedigree, RFID |
 |
Financial, Purchasing, Contract Administration |  |
Trade/Industry Relations, Sales and Marketing |
 |
Government, Regulatory |  |
Supply Chain, Operations, Logistics, Distribution |
 |
Specialty Distribution Focus Track Sponsored by Takeda Pharmaceuticals North America, Inc. and Vertex Pharmaceuticals, Inc. |
 |
International Focus |
 |
Professional Development | ||
| MONDAY, MARCH 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Opening General Session | 8:30 AM–9:45 AM Welcome Address
Common Ground
Savvy political analysts and authors Bob Beckel and Cal Thomas take their political differences and find the “common ground” that unites all Americans. Although Beckel, a liberal, and Thomas, a conservative, have different opinions on almost every subject imaginable, the goal of “Common Ground” is to show that bridges can be forged between political differences, and agreements can be made. By openly discussing their differences, respecting each other’s opinions, and thoughtfully recognizing the validity of every view and opinion, they open up the doors for civil discourse, and hope to usher in a new era of American politics. More like a conversation between friends than a debate between enemies, their presentation will inspire audiences to find the common ground in their own beliefs, and put aside “politics as usual.” Concurrent Business, Policy and Technology Sessions
A1: Leveraging Data: Current Trends in the Healthcare Supply Chain As trading partner relationships evolve, there is increasing talk of making channel data among stakeholders more transparent. This session will explore the meaning behind the data as product sales are matched to product movement and financials flow to support better decision making. With the new focus on specialty distribution and a developing need to seek common ground in emerging channel relationships, examine the past and look to the future in this timely discussion of data.
A2: State of the States State pedigree and licensing laws continue to challenge manufacturers and distributors alike as they strive to preserve efficiencies in the supply chain. States also are addressing controlled substance issues in addition to recent drug shortages. Get the latest updates on these and other timely proposals at the state level.
A3: Pharmaceutical Supply Chain Integrity Supply chain integrity integrates the many aspects of Good Distribution Practices (GDPs) in the pharmaceutical supply chain, including the three important components comprising GDPs: Good Cold Chain Practices (GCCPs), Good Import Practices (GIPs) and Distribution Control Systems (DCS). This session will offer perspectives on how maintaining supply chain integrity has expanded to integrate best practices for supply chain safety and security from manufacturing through distribution to fulfill both trading-partner business agreements and evolving national and global regulatory requirements. Concurrent Business, Policy and Technology Sessions
B1: A View from the DEA: Trends, Regulations and Interpretations A representative from the Drug Enforcement Administration (DEA) will provide an update on the ever-changing world of controlled substances, listed chemicals, inspections and other topics. An opportunity for questions and answers also will be provided.
B3: Losing Exclusivity, Gaining Returns? The "patent cliff" has arrived, with many high-volume brands beginning to face generic competition. Whenever a company's brand loses exclusivity, it works to manage expectations between demand forecasts and actual inventory to diminish the impact of returns. In this session, dissect an actual product life cycle example and discuss how trading partners can cooperate to effectively manage this type of event.
B4: Going Global: Building Business Outside the U.S. Ensuring a wide international presence has been a long-held strategy of many pharmaceutical companies. Hear how different companies are growing and expanding product lines outside the U.S. and moving into countries including Canada, Europe, Latin America and Asia. Gain valuable perspectives, insights and key takeaways from leveraging outside resources or choosing to invest in the infrastructure necessary to be competitive. Concurrent Business, Policy and Technology Sessions
C1: International Perspectives on Serialization Serialization has been implemented differently in other countries. Keeping abreast of the requirements for authentication and track-and-trace and the potential impact on implementation efforts in the U.S. healthcare supply chain is important to your business. Hear about serialization requirements outside the U.S. during this session.
C2: Negotiation Tips and Strategies Negotiation skills are an essential tool in today’s business world – whether you are closing a deal or resolving a conflict. This session will equip you with tips and strategies for your comprehensive negotiation plan. Real-world examples will be shared demonstrating how the tools work in everyday business situations. You will be able to plan for your next challenging conversation, analyze points of resistance and navigate through each step in the process; knowing what to say, what to ask for and what to give and take.
C3: Managing Cold Chain Products As the number of products requiring cold chain handling increases, this session will explore how trading partners can effectively manage the distribution of cold chain products to customers while enhancing the safety and security of the healthcare supply chain. Review regulatory considerations and manufacturer expectations for managing cold chain products in the supply chain, and see the latest techniques to properly maintain temperature-sensitive products. Concurrent Business, Policy and Technology Sessions
D1: When Will Biosimilars Reach the U.S. Healthcare Market? With the passage the Affordable Care Act, a regulatory pathway now exists for the FDA to review and approve biosimilar versions of existing biologic medicines. But while Congress gave the FDA statutory authority, the agency is still in the process of developing regulations to implement the law. Europe, on the other hand, has had a biosimilars program in place for a number of years. What lessons can the FDA learn from its European counterpart about the process of reviewing and approving biosimilars? Examine the opportunities and challenges that lay ahead for biosimilars in the U.S.
B2: Serialization and Secure Distribution Combating counterfeiting, diversion, adulteration and illegal importation is a high priority for the pharmaceutical industry and government agencies — and essential to ensure patient safety. In this session you will learn how one manufacturer has leveraged serialization to implement a secure distribution program for some of its high-risk products. The program not only has helped this company manage its supply chain from manufacturing all the way to the point of dispense, but also was instrumental in mitigating diversion and counterfeiting. Additionally, this session will outline risks, opportunities and other essential security measures needed to consider when rolling out programs.
D3: Developing Supply Chain Talent Facing what is often referred to as a "talent crisis," recruiting, developing and retaining the right mix of staff is one of the top priorities in the healthcare industry. This session will include a hands-on discussion and a host of practical suggestions as you look to fill your supply chain management pipeline with leadership and functional expertise in the areas where you need it most. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TUESDAY, MARCH 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Morning General Session and Distribution Management Award Presentation | 8:00 AM–9:15 AM Distribution Management Award Presentation For more information about the nomination process, contact Lisa Gallagher, Director of Member Services, at (703) 885-0251 or e-mail lgallagher@hdmanet.org.
New Research: The Role of Distributors in the U.S. Healthcare Industry
Booz & Company — in conjunction with HDMA’s research foundation, the Center for Healthcare Supply Chain Research — will highlight the findings of a newly updated study, The Role of Distributors in the U.S. Healthcare Industry. Previously issued in 2004 and 2007, the study highlights the value and operational efficiencies distributors provide to the healthcare industry. The 2011 analysis not only examines the fee-for-service model, the growth of generics and specialty products in wake of the industry “patent cliff,” but also analyzes such issues as healthcare reform, the challenging economic climate and the heightened regulations affecting the supply chain today.
Concurrent Business, Policy and Technology Sessions
E1: Controlled Substance Monitoring — Manufacturer Perspectives Explore the DEA's stepped-up scrutiny of efforts to monitor suspicious orders of controlled substances, how evolving DEA enforcement affects registrants and appropriate the actions to help ensure compliance. Understand manufacturer compliance strategies and discuss specific examples in response to DEA's changing regulatory and enforcement actions. Using a case-study approach, the emphasis will be on manufacturer impacts and strategies. However, wholesalers will find the session discussion, including such areas as interactions between them and their suppliers, of interest.
E2: Developing an Effective Commercialization Strategy Emerging and newly commercial pharmaceutical manufacturers face many issues while bringing a product to market. Understand the important questions that can drive your product distribution channel — and your commercialization strategy — directly from experts who have successfully managed this process. Review the various roles specialty pharmacies and distributors, community pharmacists and manufacturers play in developing product pipelines. Learn the rationale for emerging distribution trends and why these trends are here to stay.
E3: How Hospitals Generate ROI and Improve Patient Safety with Serialization This session showcases how track-and-trace technology is being used in the hospital environment and provides valuable benefits such as operational process optimization, asset tracking, patient safety, security and more. Concurrent Business, Policy and Technology Sessions
F1: Protecting the Supply Chain With pharmaceutical companies (and their suppliers) facing a more complex and global supply chain, enhancing the traceability, visibility and security of the healthcare supply chain is critical. Industry experts will share best practices and the latest strategies, tactics and recommendations used globally to combat theft both in warehouses and while in transit.
F2: CMS and the Future of AMP
Learn the critical information about the potential policy changes resulting from CMS's new proposed rule to calculate Medicaid's average manufacturers price (AMP) reimbursement formula. Delve into the latest updates on federal reimbursement metrics for pharmaceuticals under the Medicare and Medicaid programs. This session will primarily focus on the new AMP formula and its potential impact and changes to definitions of key reimbursement terms, manufacturer reporting requirements and the development and use of average acquisition cost (AAC) as a reimbursement metric. Hear how these legislative and regulatory changes will affect the way you do business.
F3: Bar Code Labeling in the Healthcare Supply Chain With ongoing pressure to reduce healthcare costs and improve patient safety, healthcare supply chain professionals need to identify and refine how proven technologies are used to increase the efficiency of supply chain procurement, replenishment and other logistical processes — and enhance the quality of patient care in the U.S. and worldwide. Hear highlights from HDMA's new Guidelines for Bar Coding in the Pharmaceutical Supply Chain, which focus on serialization, incorporate changes to the shipping container label bar code formats, examine how a company could implement SNI and more. Concurrent Business, Policy and Technology Sessions
G1: Federal Pedigree Update The existing patchwork of state pedigree laws continues to challenge manufactures and distributors alike as they strive to preserve efficiencies in the supply chain. Learn about recent legislative and regulatory developments and what Congress, FDA and industry stakeholders are doing to address them at the federal level.
G2: The Facts, Figures and Trends in Healthcare Get a broader picture of the healthcare supply chain facts, figures and trends in an informative session presented by the Center for Healthcare Supply Chain Research, HDMA's research foundation. Analyze the latest industry benchmarks reported in both the third edition of Specialty Pharmaceuticals: Facts, Figures and Trends and the 2011–2012 HDMA Factbook.
G3: Transportation Trends Transportation plays a vital role in supply chain management. Against a backdrop of current issues and regulations facing the supply chain, this session will explore strategies to assess your shipper, carrier or service provider relationships, as they in turn face pressures surrounding fuel costs, capacity constraints, driver supply and retention and more. Focusing specifically on trucking and "last-mile" carriers, gain an understanding of how your transportation networks can meet the needs of the future. Afternoon General Session | 2:45 PM–4:00 PM What’s In, What’s Out, What’s Ahead: 2012 Healthcare Marketplace Trends
Doug Long, an industry thought leader who specializes in analyzing information from IMS Health’s premier sales, prescription, promotional and medical databases, will take a first look at the latest industry data and emerging market trends for branded and generic pharmaceutical and health and beauty care product sales. Long will offer his perspective on a range of vital pharmaceutical topics, including global market trends, industry forecasts, research and development, marketing practices, blockbuster drugs, patent expirations and generic trends, biotechnology and more. He also will analyze how emerging trends will affect strategic business plans in the coming year and beyond.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| WEDNESDAY, MARCH 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Closing General Session | 8:30 AM–11:00 AM Sabato’s Crystal Ball
What does it take to know the results of an election before it happens? How can you predict the winners — with 99 percent accuracy — of every congressional, senatorial and gubernatorial race in the country, while also predicting the Electoral College count with the smallest possible margin of error? Dr. Larry J. Sabato will share his ‘Crystal Ball’ electoral analysis that leads him to expertly navigate the shifting sands of American electoral politics, accurately predicting the landslides, the nail-biters, and everything in between.
Executive Panel: Distribution Trends and Perspectives
This executive-level distributor panel will focus on new business realities brought about by evolving healthcare industry and government trends. Explore the dynamic business changes ahead that will impact how distributors will meet future patient demands for value, efficiency and safety. What is the real effect of new distribution models, including specialty distribution and third-party logistics? How will healthcare distributors differentiate services, leverage relationships and efficiently serve customers in a new business environment? The conversation will help analyze the events and trends that may affect stakeholders across the healthcare distribution channel, impact decision-making and influence change. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HDMA’s Distribution Management Award recognizes HDMA member companies’ efforts to improve the efficiency and effectiveness of the healthcare supply chain and enhance trading partner relationships. All HDMA members are eligible to nominate their company or a valued trading partner for this prestigious award. . Last year we honored ValueCentric, LLC, with this prestigious award for its ValueTrak Safe & Secure Supply Chain Module. 
